Treating cancer when pRb and p53 cannot be reactivated

Liang Zhu

doi:10.1080/23723556.2015.1004954

Treating cancer when pRb and p53 cannot be reactivated

Liang Zhu

Research output: Contribution to journal › Article › peer-review

Abstract

Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.

Original language	English (US)
Article number	e1004954
Journal	Molecular and Cellular Oncology
Volume	2
Issue number	4
DOIs	https://doi.org/10.1080/23723556.2015.1004954
State	Published - Oct 2 2015
Externally published	Yes

Keywords

Skp2
cancer therapy
genetic inactivation
miR-17-92
p53
pRb

ASJC Scopus subject areas

Molecular Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/23723556.2015.1004954

Cite this

@article{88a9888134774154aef16f56c64d55ce,

title = "Treating cancer when pRb and p53 cannot be reactivated",

abstract = "Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.",

keywords = "Skp2, cancer therapy, genetic inactivation, miR-17-92, p53, pRb",

author = "Liang Zhu",

note = "Publisher Copyright: {\textcopyright} 2015, {\textcopyright} 2015 The Author(s). Published with license by Taylor & Francis Group, LLC. {\textcopyright} 2015, {\textcopyright} Liang Zhu.",

year = "2015",

month = oct,

day = "2",

doi = "10.1080/23723556.2015.1004954",

language = "English (US)",

volume = "2",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Treating cancer when pRb and p53 cannot be reactivated

AU - Zhu, Liang

PY - 2015/10/2

Y1 - 2015/10/2

N2 - Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.

AB - Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.

KW - Skp2

KW - cancer therapy

KW - genetic inactivation

KW - miR-17-92

KW - p53

KW - pRb

UR - http://www.scopus.com/inward/record.url?scp=85051466297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051466297&partnerID=8YFLogxK

U2 - 10.1080/23723556.2015.1004954

DO - 10.1080/23723556.2015.1004954

M3 - Article

AN - SCOPUS:85051466297

SN - 2372-3556

VL - 2

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 4

M1 - e1004954

ER -

Treating cancer when pRb and p53 cannot be reactivated

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this